FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012148544> ?p ?o ?g. }

• W2012148544 endingPage "465" @default.
• W2012148544 startingPage "461" @default.
• W2012148544 abstract "We investigated the pharmacokinetics of bromocriptine and octreotide, both individually and in combination, in 12 patients with active acromegaly. The pharmacodynamics of the drugs were assessed by 12-h profiles of GH secretion and insulin-like growth factor-I (IGF-I) measurements. During the 42-day study period, bromocriptine was administered for 28 days (from day 8; 5 mg, orally, twice daily) and octreotide (200 micrograms, sc, twice daily) from days 15-42. IGF-I levels, 12-h GH, and plasma bromocriptine and octreotide profiles were obtained on days 0, 14, 28, and 42. During bromocriptine treatment, both the area under the GH day curves (AUC) and mean IGF-I decreased to 64% (95% confidence limits, 43-72% and 48-82%, respectively) of initial values. During octreotide treatment, the respective values were 23% (18-30%) and 32% (21-36%), which were greater decreases than those during bromocriptine treatment [36% (95% confidence limits, 32-54%) for AUC for GH and 50% (95% confidence limits, 34-58%) for IGF-I]. With combined treatment, the AUC for GH was reduced to 16% (12-21%) and that of IGF-I to 25% (16-27%) of initial values. This combination was more effective than bromocriptine [25% (95% confidence limits, 22-37%) for AUC for GH and 39% (95% confidence limits, 25-43%) for IGF-I] and octreotide alone [78% (95% confidence limits, 53-89%) for AUC for GH and 78% (95% confidence limits, 57-98%) for IGF-I]. The pharmacokinetic parameters of octreotide were unchanged by the coadministration of bromocriptine. The bioavailability of bromocriptine increased by approximately 40% when bromocriptine was administered together with octreotide compared with administration alone (P < 0.01). Bromocriptine disposition parameters were unaltered. In conclusion, treatment of acromegalics with a combination of octreotide and bromocriptine increases the bioavailability of bromocriptine and reduces both GH and IGF-I levels more effectively than treatment with either drug alone. This presents the possibility of less frequent drug administrations, lower doses of octreotide, and, consequently, lower treatment costs." @default.
• W2012148544 created "2016-06-24" @default.
• W2012148544 creator A5020174799 @default.
• W2012148544 creator A5025545871 @default.
• W2012148544 creator A5029997255 @default.
• W2012148544 creator A5037611057 @default.
• W2012148544 creator A5054385542 @default.
• W2012148544 creator A5071721348 @default.
• W2012148544 creator A5078323979 @default.
• W2012148544 creator A5089817546 @default.
• W2012148544 date "1994-08-01" @default.
• W2012148544 modified "2023-10-13" @default.
• W2012148544 title "A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly." @default.
• W2012148544 cites W1553253964 @default.
• W2012148544 cites W1970258174 @default.
• W2012148544 cites W1972650975 @default.
• W2012148544 cites W1982357798 @default.
• W2012148544 cites W2005614064 @default.
• W2012148544 cites W2012615488 @default.
• W2012148544 cites W2017602672 @default.
• W2012148544 cites W2025997743 @default.
• W2012148544 cites W2030579930 @default.
• W2012148544 cites W203404296 @default.
• W2012148544 cites W2038594553 @default.
• W2012148544 cites W2047702417 @default.
• W2012148544 cites W2052910600 @default.
• W2012148544 cites W2066167958 @default.
• W2012148544 cites W2067868348 @default.
• W2012148544 cites W2071369211 @default.
• W2012148544 cites W2083894069 @default.
• W2012148544 cites W2090065340 @default.
• W2012148544 cites W2092766569 @default.
• W2012148544 cites W2156966502 @default.
• W2012148544 cites W2267726834 @default.
• W2012148544 doi "https://doi.org/10.1210/jcem.79.2.8045964" @default.
• W2012148544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8045964" @default.
• W2012148544 hasPublicationYear "1994" @default.
• W2012148544 type Work @default.
• W2012148544 sameAs 2012148544 @default.
• W2012148544 citedByCount "35" @default.
• W2012148544 countsByYear W20121485442012 @default.
• W2012148544 countsByYear W20121485442013 @default.
• W2012148544 countsByYear W20121485442014 @default.
• W2012148544 countsByYear W20121485442017 @default.
• W2012148544 countsByYear W20121485442018 @default.
• W2012148544 countsByYear W20121485442020 @default.
• W2012148544 crossrefType "journal-article" @default.
• W2012148544 hasAuthorship W2012148544A5020174799 @default.
• W2012148544 hasAuthorship W2012148544A5025545871 @default.
• W2012148544 hasAuthorship W2012148544A5029997255 @default.
• W2012148544 hasAuthorship W2012148544A5037611057 @default.
• W2012148544 hasAuthorship W2012148544A5054385542 @default.
• W2012148544 hasAuthorship W2012148544A5071721348 @default.
• W2012148544 hasAuthorship W2012148544A5078323979 @default.
• W2012148544 hasAuthorship W2012148544A5089817546 @default.
• W2012148544 hasConcept C112705442 @default.
• W2012148544 hasConcept C126322002 @default.
• W2012148544 hasConcept C134018914 @default.
• W2012148544 hasConcept C2776297358 @default.
• W2012148544 hasConcept C2776856834 @default.
• W2012148544 hasConcept C2777433750 @default.
• W2012148544 hasConcept C2779064019 @default.
• W2012148544 hasConcept C2781025020 @default.
• W2012148544 hasConcept C2984496839 @default.
• W2012148544 hasConcept C44249647 @default.
• W2012148544 hasConcept C71315377 @default.
• W2012148544 hasConcept C71924100 @default.
• W2012148544 hasConcept C76318530 @default.
• W2012148544 hasConceptScore W2012148544C112705442 @default.
• W2012148544 hasConceptScore W2012148544C126322002 @default.
• W2012148544 hasConceptScore W2012148544C134018914 @default.
• W2012148544 hasConceptScore W2012148544C2776297358 @default.
• W2012148544 hasConceptScore W2012148544C2776856834 @default.
• W2012148544 hasConceptScore W2012148544C2777433750 @default.
• W2012148544 hasConceptScore W2012148544C2779064019 @default.
• W2012148544 hasConceptScore W2012148544C2781025020 @default.
• W2012148544 hasConceptScore W2012148544C2984496839 @default.
• W2012148544 hasConceptScore W2012148544C44249647 @default.
• W2012148544 hasConceptScore W2012148544C71315377 @default.
• W2012148544 hasConceptScore W2012148544C71924100 @default.
• W2012148544 hasConceptScore W2012148544C76318530 @default.
• W2012148544 hasIssue "2" @default.
• W2012148544 hasLocation W20121485441 @default.
• W2012148544 hasLocation W20121485442 @default.
• W2012148544 hasOpenAccess W2012148544 @default.
• W2012148544 hasPrimaryLocation W20121485441 @default.
• W2012148544 hasRelatedWork W1968754618 @default.
• W2012148544 hasRelatedWork W1974073575 @default.
• W2012148544 hasRelatedWork W1977703910 @default.
• W2012148544 hasRelatedWork W1985225714 @default.
• W2012148544 hasRelatedWork W2006359830 @default.
• W2012148544 hasRelatedWork W2027596383 @default.
• W2012148544 hasRelatedWork W2050965375 @default.
• W2012148544 hasRelatedWork W2068535273 @default.
• W2012148544 hasRelatedWork W2074276321 @default.
• W2012148544 hasRelatedWork W2084287748 @default.
• W2012148544 hasVolume "79" @default.
• W2012148544 isParatext "false" @default.

• next